Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Serum M protein ≥1.5 g/dL (HR 18.9 [95% CI, 1.8-200.8]; P=0.015) and hypoalbuminemia (HR 14.7 [95% CI, 1.7-124.7]; P=0.014) are independent prognostic factors for progression from MGUS; may be added to prognostic models.”
Title: Hypoalbuminemia: a new risk factor for progression in patients with monoclonal gammopathy of uncertain significance
Authors: Elena Alejo, Verónica González-Calle, Patricia Blázquez, Borja Puertas, Cristina Agulló, Beatriz Rey-Búa, Norma C. Gutiérrez, Noemi Puig, María-Victoria Mateos
You can read the Full Article in Blood Cancer Journal.
You can find more posts featuring Robert Orlowski on OncoDaily.
